Do Institutional Investors Love CONCERT PHARMACEUTICALS (NYSE:JMPC)?

July 26, 2017 - By Adrian Erickson

 Do Institutional Investors Love CONCERT PHARMACEUTICALS (NYSE:JMPC)?

Sentiment for CONCERT PHARMACEUTICALS (NYSE:JMPC)

CONCERT PHARMACEUTICALS (NYSE:JMPC) institutional sentiment increased to 1.36 in 2016 Q4. Its up 0.36, from 1 in 2016Q3. The ratio has improved, as 45 investment professionals opened new or increased holdings, while 33 sold and reduced their equity positions in CONCERT PHARMACEUTICALS. The investment professionals in our partner’s database now possess: 12.41 million shares, down from 12.71 million shares in 2016Q3. Also, the number of investment professionals holding CONCERT PHARMACEUTICALS in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 21 Increased: 32 New Position: 13.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $561.63 million. The Firm is engaged in the discovery and development of small molecule drugs. It currently has negative earnings. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others.

The stock decreased 0.22% or $0.06 on July 25, reaching $25.3. About shares traded. Concert Pharmaceuticals Inc (NYSE:JMPC) has 0.00% since July 26, 2016 and is . It has underperformed by 16.70% the S&P500.

More recent Concert Pharmaceuticals Inc (NYSE:JMPC) news were published by: Benzinga.com which released: “18 Biggest Mid-Day Gainers For Monday” on July 24, 2017. Also Businesswire.com published the news titled: “Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656” on July 25, 2017. Seekingalpha.com‘s news article titled: “Concert Pharmaceuticals Provides Investment Opportunity With Deuterated Drug …” with publication date: July 10, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.